NEW YORK, Feb 15 - Aurora Biosciences said Thursday its fourth-quarter revenue slipped 17 percent to $16.5 million, compared with $19.9 million in the year ago period. 

The San Diego-based company did not offer a reason why its revenues dropped but noted that it generated revenues from such deals as an exclusive collaboration with Senomyx to develop consumer products that enhance taste and olfaction, a licensing agreement with Deltagen, and an ion channel technology agreement with GlaxoSmithKline.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.